Late cardiotoxicity of high-dose chemotherapy according to the modified NHL-BFM-90 program in adult patients with diffuse large B-cell lymphoma
- Authors: Dorokhina EI1, Magomedova AU1, Shevelev AA1, Kulikov SM1, Gitis MK1, Vedernikov AV1, Vorobyev AI1, Kravchenko SK1
-
Affiliations:
- «Гематологический научный центр» Минздрава России
- Issue: Vol 87, No 7 (2015)
- Pages: 51-57
- Section: Editorial
- URL: https://journals.rcsi.science/0040-3660/article/view/31770
- ID: 31770
Cite item
Full Text
Abstract
About the authors
E I Dorokhina
«Гематологический научный центр» Минздрава РоссииМосква, Россия
A U Magomedova
«Гематологический научный центр» Минздрава РоссииМосква, Россия
A A Shevelev
«Гематологический научный центр» Минздрава РоссииМосква, Россия
S M Kulikov
«Гематологический научный центр» Минздрава РоссииМосква, Россия
M K Gitis
«Гематологический научный центр» Минздрава РоссииМосква, Россия
A V Vedernikov
«Гематологический научный центр» Минздрава РоссииМосква, Россия
A I Vorobyev
«Гематологический научный центр» Минздрава РоссииМосква, Россия
S K Kravchenko
«Гематологический научный центр» Минздрава РоссииМосква, Россия
References
- Campo E, Swerdlow SH, Harris NL, Pileri S, Stein H, Jaffe ES. The 2008 WHO classification of lymphoid neoplasms and beyond: evolving concepts and practical applications. Blood. 2011;117(19):5019-5032.
- Воробьев А.И. Руководство по гематологии. Т. 2. М.: Ньюдиамед; 2003:55, 98-100.
- Jerkeman M, Anderson H, Cavallin-Ståhl E, Dictor M, Hagberg H, Johnson A, Kaasa S, Kvaløy S, Sundström C, Akerman M. CHOP versus MACOP-B in aggressive lymphoma — a Nordic Lymphoma Group randomized trial. Ann Oncol. 1999;10(9):1079-1086.
- Hasselblom S, Ridell B, Nilsson-Ehle H, Andersson PO. The impact of gender, age and patient selection on prognosis and outcome in diffuse large B-cell lymphoma — a population-based study. Leuk Lymphoma. 2007;48(4):736-745.
- Horning S, Weller E, Kim KM, Earle JD, O’Connell MJ, Habermann TM, Glick JH. Chemotherapy with or without radiotherapy in limited-stage diffuse aggressive non-Hodgkins lymphoma: Eastern Cooperative Oncology Group Study 1484. J ClinOncol. 2004;22(15):3032-3038.
- Fisher RI, Gaynor ER, Dahlberg S, Oken MM, Grogan TM, Mize EM, Glick JH, Coltman CA Jr, Miller TP. Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin’s lymphoma. New Engl J Med. 1993;328:1002-1006.
- Магомедова А.У., Кравченко С.К., Кременецкая А.М., Звонков Е.А., Барях Е.А., Мангасарова Я.К., Воробьев А.И. Девятилетний опыт лечения больных диффузной В-крупноклеточной лимфосаркомой. Терапевтический архив. 2011;7:5-10.
- Coiffier B, Thieblemont C, Van Den Neste E, Lepeu G, Plantier I, Castaigne S, Lefort S, Marit G, Macro M, Sebban C, Belhadj K, Bordessoule D, Fermé C, Tilly H. Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d’Etudes des Lymphomes de l’Adulte. Blood. 2010;116(12):2040-2045.
- Michael Pfreundschuh, Evelyn Kuhnt. CHOP-like chemotherapy with or without rituximab in young patients with good-prognosis diff use large-B-cell lymphoma: 6-year results of an open-label randomized study of the MabThera International Trial (MInT) Group. Lancet Oncol. 2011;12:1013-1022.
- Zvonkov E. Six-year experience in the treatment of primary aggressive gastric lymphomas with modified NHL-BFM-90 protocol. Haematologica. 2010;95:632-632.
- Звонков Е.Е., Кременецкая А.М., Кравченко С.К., Махиня В.А., Капланская И.Б., Обухова Т.Н., Воробьев И.А. Эффективность консервативной терапии лимфосаркомы желудка. Терапевтический архив. 2008;7:18-26.
- Кравченко С.К., Магомедова А.У., Замятина В.А., Марголин О.В. Высокодозная терапия генерализованной формы (без вовлечения костного мозга) диффузной В-крупноклеточной лимфосаркомы у больных старшего возраста. Гематология итрансфузиология. 2008;53(3):6-9.
- Jones RL, Ewer MS. Cardiac and cardiovascular toxicity of nonanthracycline anticancer drugs. Expert Rev Antican Ther. 2006;6(9):1249-1269.
- Schimmel KJ, Richel DJ, van den Brink RB, Guchealaar HJ. Cardiotoxicity of cytotoxic drugs. Cancer Treat Rev. 2004;30(2): 181-191.
- Yeh ET. Cardiotoxicity induced by chemotherapy and antibody therapy. Ann Rev Med. 2006;57:485-498.
- Yeh ET, Tong AT, Lenihan DJ, Yusuf SW, Swafford J, Champion C, Durand JB, Gibbs H, Zafarmand AA, Ewer MS. Cardiovascular complications of cancer therapy: diagnosis, pathogenesis, and management. Circulation. 2004;109(25):3122-3131.
- Myers C. Role of iron in anthracycline action. In: Hacker M, Lazo J, Tritton T, eds. Organ Directed Toxicities of Anticancer Drugs. Boston, Mass: Martinus Nijhoff; 1988:17-30.
- Lewis W, Kleinerman J, Puszkin S. Interaction of Adriamycin in vitro with cardiac myofibril proteins. Canc Res. 1982;50:547-553.
- Chaiswing L, Cole MP, St Clair DK, Ittarat W, Szweda LI, Oberley TD. Oxidative damage precedes nitrative damage in adriamycin-induced cardiac mitochondrial injury. Toxicol Pathol. 2004;32(5):536-547.
- Kupari M, Volin L, Suokas A, Timonen T, Hekali P, Ruutu T. Cardiac involvement in bone marrow transplantation: electrocardiographic changes, arrhythmias, heart failure and autopsy findings. Bone Marrow Transplant. 1990;5:91-98.
- Quezado ZM, Wilson WH, Cunnion RE, Parker MM, Reda D, Bryant G, Ognibene FP. High-dose ifosfamide is associated with severe, reversible cardiac dysfunction. Ann Intern Med. 1993;118:31-36.
- Yancey RS, Talpaz M. Vindesine-associated angina and ECG changes. Cancer Treat Rep. 1982;66:587-589.
- Airey CL, Dodwell DJ, Joffe JK, Jones WG. Etoposide-related myocardial infarction. Clin Oncol. 1995;7:135.
- Chaladze T, Megreladze I, Zodelava M. Early cardiotoxicity induced by treatment of hematologic malignancies and the riskfactors of its manifestation. Georgian Med News. 2005;129:117-119.
- Pai VB, Nahata MC. Cardiotoxicity of chemotherapeutic agents: incidence, treatment and prevention. Drug Saf. 2000;22(4):263-302.
- Benjamin R. The schedule dependency of the cardiotoxicity of adriamycin: its relevance to pharmacokinetic parameters. In: Muggia F, ed. Cancer Treatment and the Heart. Baltimore, Md: The Johns Hopkins University Press; 1992:278.
- Lipshultz SE, Lipsitz SR, Sallan SE, Dalton VM, Mone SM, Gelber RD, Colan SD. Chronic progressive cardiac dysfunction years after doxorubicin therapy for childhood acute lymphoblastic leukemia. J Clin Oncol. 2005;23(12):2629-2636.
- Lipshultz SE. Exposure to anthracyclines during childhood causes cardiac injury. Semin Oncol. 2006;33(3):8-14.
- Elbl L, Chaloupka V, Vásová I, Kiss I, Jancík J, Vorlícek J, Navrátil M. Changes in left ventricular function during chemotherapy with doxorubicin. Vnitr Lek. 1999;45(7):395-402.
- Hequet O, Le QH, Moullet I, Pauli E, Salles G, Espinouse D, Dumontet C, Thieblemont C, Arnaud P, Antal D, Bouafia F, Coiffier B. Subclinical late cardiomyopathy after doxorubicin therapy for lymphoma in adults. J Clin Oncol. 2004;22(10):1864-1871.
- Moser EC, Noordijk EM, van Leeuwen FE, le Cessie S, Baars JW, Thomas J, Carde P, Meerwaldt JH, van Glabbeke M, Kluin-Nelemans HC. Long-term risk of cardiovascular disease after treatment for aggressive non-Hodgkin lymphoma. Blood. 2006;107:2912-2919.
- Hershman DL, McBride RB, Eisenberger A, Tsai WY, Grann VR, Jacobson JS. Doxorubicin, cardiac risk factors, and cardiac toxicity in elderly patients with diffuse B-cell non-Hodgkin’s lymphoma. JClin Oncol. 2008;26:3159-3165.
- Мареев В.Ю., Агеев Ф.Т., Арутюнов Г.П., Коротеев А.В., Ревишвили А.Ш., Беленков Ю.Н., Поздняков Ю.А. Национальные рекомендации ВНОК и ОССН по диагностике и лечению ХСН (третий пересмотр). Сердечная недостаточность. 2010;11(1):1-62.
- Grenier MA, Lipshultz SE. Epidemiology of anthracycline cardiotoxicity in children and adults. Semin Oncol. 1998;25(4):Suppl. 10:72-85.
- Jensen BV, Skovsgaard T, Nielsen SL. Functional monitoring of anthracycline cardiotoxicity: a prospective, blinded, long-term observational study of outcome in 120 patients. Ann Oncol. 2002; 13:5:699-709.
- Jensen BV. Cardiotoxic consequences of anthracyclinecontaining therapy in patients with breast cancer. Semin Oncol. 2006;33(3):Suppl. 8:15-21.
- Chaladze T, Megreladze I, Zodelava M. Early cardiotoxicity induced by treatment of hematologic malignancies and the riskfactors of its manifestation. Georgian Med News. 2005;129:117-119.
- Aggarwal S, Pettersen MD, Bhambhani K, Gurczynski J, Thomas R, L’Ecuyer T. B-type natriuretic peptide as a marker for cardiac dysfunction in anthracyclinetreated children. Pediatr Blood Cancer. 2006;43:12.
![](/img/style/loading.gif)